[A nosocomial epidemic of Salmonella mbandaka which produces various broad spectrum beta-lactamases: preliminary results].
During a nosocomial epidemic of Salmonella mbandaka in Algeria, 99 strains were isolated from specimens. Study of 22 of them revealed minimum inhibiting concentrations ranged from 4 to 32 micrograms/ml for cefotaxime, 2 to 32 micrograms/ml for ceftazidime and 2 to 16 micrograms/ml for ceftriaxione. The mechanism underlying resistance was enzymatic with production of broad-spectrum beta-lactamase enzyme. Clavulinic acid at a dose of 2 micrograms/ml restored the activity of hydrolyzed beta-lactamases. Resistance to all antibiotics including cefotaxime was due to a single plasmid structure. The plasmid did not belong to any known compatibility group. All strains studied contained a plasmid of 26MDa and produced TEM-1 and TEM-2 beta-lactamases. Strains resistant to cefotaxime also synthetized a broad-spectrum beta-lactamase derived from TEM.
Rahal
K
K
Service de Bactériologie Médicale, d'Antibiothérapie et d'Hygiène Hospitalière, Institut Pasteur d'Alger, Algérie.
Reghal
A
A
D000462:Algeria; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use; D018550:Cephalosporin Resistance / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology*; D004269:DNA, Bacterial / Q000032:analysis; D004196:Disease Outbreaks; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010957:Plasmids / Q000032:analysis; D012475:Salmonella / Q000145:classification / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification*; D012480:Salmonella Infections / Q000382:microbiology*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D004269:DNA, Bacterial; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D002443:Ceftriaxone; D002442:Ceftazidime; D001618:beta-Lactamases; D002439:Cefotaxime
Epidémie nosocomiale à Salmonella mbandaka productrices de différentes beta-lactamases dont une à large spectre: Résultats préliminaires.